Dupilumab De-escalation in Pediatric Atopic Dermatitis

NCT06116526 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: Dupilumab - Discontinuation
DRUG: Dupilumab - Dose Reduction
DRUG: Dupilumab - Standard Dose

Sponsor

Johns Hopkins University

Collaborators

[object Object]